PROTAC Linkers and their role in developing cancer therapeutics


Novel approaches are always being sought in the dynamic field of cancer therapies to tackle the difficulties presented by historically elusive pharmacological targets. A novel strategy that is gaining popularity is the application of Proteolysis-Targeting Chimeras (PROTACs). These molecules have shown tremendous promise in the selective degradation of disease-causing proteins, providing novel therapeutic options for cancer (1).

Heterobifunctional compounds called proteolysis targeting chimeras (PROTACs) are made up of two ligands joined by a linker. A “warhead” ligand attaches itself to a specific protein of interest (POI) that is to be targeted, while an “anchor” ligand attaches itself to the substrate binding domain (SBD) of an E3 ubiquitin (Ub) ligase. The POI is brought into a ternary complex (TC) with the E3 ligase by the PROTAC, which binds to both proteins in cells. The ensemble is close to the POI because of the TC formation, and the E3 ligase is in complex with an active Ub-loaded E2 ligase. This causes the POI to become (poly)-ubiquitinated at lysine residues, designating it for 26S proteasome destruction (2).

An essential element at the center of PROTAC technology is the linker. Although PROTACs are well-known for their exceptional capacity to cause specific protein degradation, the importance of the linkers in coordinating these complex molecular processes is becoming more widely acknowledged. PROTAC linker properties and design are critical in determining the overall success, selectivity, and efficacy of these chimeric compounds (3).

The Unique Mechanism of PROTACs

PROTACs, or proteolysis-targeting chimeras, offer a novel mechanism that permits molecular-level precision targeting, hence presenting a paradigm-shifting approach to drug development. The capacity to specifically destroy disease-causing proteins is the basis of this creative tactic, which offers a fresh approach that is especially intriguing in the context of cancer therapies. By taking advantage of the ubiquitin-proteasome system and other cellular mechanisms involved in protein turnover, PROTACs can cause the degradation of particular proteins (4). 

When it comes to targeted protein breakdown, PROTACs’ mode of action is different from that of conventional small-molecule inhibitors, providing clear benefits. In contrast to inhibitors, which usually work by attaching to allosteric or functional sites, PROTACs function utilizing a novel, catalytic “event-driven” pharmacology. One characteristic of PROTACs’ mode of action that sets them apart is their catalytic nature. When PROTAC molecules are liberated from the Ternary Complex (TC), they can begin the degradation of many Proteins of Interest (POIs). Because of this catalytic cycle and the irreversible function of the Ubiquitin-Proteasome System (UPS), PROTACs can effectively limit cell growth at extremely low concentrations—down to picomolar levels (5).

One notable feature of PROTACs is their adaptability when it comes to binding to the POI. The warhead must have enough affinity to draw the POI into the complex; the binding site or method by which it binds to the POI need not be functionally significant. With the use of this characteristic, PROTACs can now target proteins that were previously thought to be undruggable by traditional small-molecule techniques. Proteins that are involved in protein-protein interactions (PPIs) or that lack clearly defined functional binding sites are frequently included in this category (3). The structural makeup of PROTAC linkers is crucial to this accuracy. These linkers serve as molecular tethers, joining the E3 ubiquitin ligase, which tags proteins for destruction, with the ligands that target the protein of interest (POI). By forming a ternary complex with the POI and the ubiquitin ligase, this dual interaction helps to transfer ubiquitin moieties onto the targeted protein. The proteasome then identifies the polyubiquitinated protein and marks it for degradation (6).

Optimizing Linker Design: Balancing Selectivity and Efficacy

To reduce off-target effects and improve treatment specificity, selectivity—the capacity to accurately distinguish between the target protein of interest (POI) and non-target proteins—is essential. To maximize selectivity, several tactics are used in PROTAC linker design optimization. Researchers can customize the PROTAC molecule by adjusting its length, composition, and flexibility. This will guarantee that the molecule interacts with the targeted POI and E3 ligase selectively and efficiently. Linkers that balance the dynamic interaction between the ligands and their binding sites are developed through the use of rational design principles and insights from structural investigations (7).

On the other hand, effectiveness depends on the linker’s capacity to promote a strong and effective interaction between the ligands, which will ultimately result in the breakdown of the targeted proteins. A thorough comprehension of the biological context, which includes the cellular milieu and the particular mechanisms behind the targeted protein breakdown process, is crucial to achieving optimal performance (8).

PROTAC Linkers in Action: Targeting Key Proteins in Cancer Pathways

Even though PROTAC technology is still developing, several strong case studies and illustrations highlight how flexible PROTAC linkers are when it comes to identifying particular proteins in cancer pathways to effectively limit tumor growth. Specifically targeting the relevant proteins, one notable example uses the covalent E3 ligase ligand BT1, which is connected to the natural product nimbolide, to induce BCR-ABL degradation. This presents a focused strategy for treating leukemia (9). Furthermore, selective degradation of nuclear FKBP12 was demonstrated by the use of KB02-SLF, a covalent binder of the nuclear-localized E3 ligase DCAF16. This highlights the precision that may be achieved with PROTAC linkers in pathways that are specific to nuclei (4). 

The potential of PROTAC linkers in breast cancer therapies was demonstrated by the induction of proteasomal degradation of BRD4 by a PROTAC (XH2) based on nimbolide and JQ1, which recruited the E3 ligase RNF114. Additionally, the synthesis of CDDO-JQ1 PROTAC, which promoted dose-dependent BRD4 degradation during oxidative stress, was made possible by a reversible covalent ligand (CDDO-me) for KEAP1. This highlights the versatility of reversible covalent PROTAC linkers in reacting to certain physiological conditions. This demonstrates how PROTAC linkers can specifically target important proteins implicated in cancer pathways, providing a potentially effective strategy to decrease tumors in a variety of settings (1).

Overcoming Drug Resistance

One of the biggest obstacles to the ongoing effective treatment of cancers is medication resistance. It is regularly observed that current treatments that block proteins linked to the advancement of cancer become less effective due to acquired drug resistance, which is frequently brought on by mutated or overexpressed protein targets. Proteolysis-targeting chimeras (PROTACs) provide an alternate therapeutic approach to cancer treatments by taking over the cellular ubiquitin-proteasome protein degradation machinery, which has several potential benefits (10).

PROTACs such as ARV-771 and ARV-825 show that resistance can be overcome by diversifying E3 ligases since resistance to one ligase-recruiting PROTAC does not always translate to another. The ability to adapt to mutations and maintain efficacy if existing ligands lose affinity is made possible by designing PROTACs with a variety of ligand binding sites. When PROTACs are used in conjunction with other therapies, such as immunotherapy, synergies are created that lower the chance of resistance. A proactive strategy involves early intervention based on emerging resistance patterns and ongoing monitoring (11,12).


To sum up, Proteolysis-Targeting Chimeras (PROTACs) are a novel class of cancer therapies that selectively degrade disease-causing proteins through ubiquitin proteasome systems. Unlike conventional inhibitors, PROTACs have a distinct catalytic and event-driven pharmacology that enables targeted targeting of cancer-related proteins. To achieve a balance between selectivity and efficacy and guarantee successful interactions, PROTAC linker tuning is essential. Case studies show how flexible PROTAC linkers are in focusing on certain proteins within cancer pathways, providing therapeutic options for leukemia and breast cancer. Notably, by diversifying E3 ligases and responding to mutations, PROTACs exhibit potential in combating drug resistance. PROTAC linkers are positioned as a viable path for the advancement of tailored and successful cancer treatments because of their comprehensive approach and proactive resistance management.


1. Rutherford KA, McManus KJ. PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer. Molecular Cancer Therapeutics [Internet]. 2024 [cited 2024 Feb 5]; Available from:

2. Liu J, Ma J, Liu Y, Xia J, Li Y, Wang ZP, et al. PROTACs: A novel strategy for cancer therapy. In: Seminars in Cancer Biology [Internet]. Elsevier; 2020 [cited 2024 Feb 5]. p. 171–9. Available from:

3. Troup RI, Fallan C, Baud MG. Current strategies for the design of PROTAC linkers: a critical review. Exploration of Targeted Anti-tumor Therapy. 2020;1(5):273. 

4. Nalawansha DA, Crews CM. PROTACs: an emerging therapeutic modality in precision medicine. Cell chemical biology. 2020;27(8):998–1014. 

5. Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery. 2022;21(3):181–200. 

6. Qi SM, Dong J, Xu ZY, Cheng XD, Zhang WD, Qin JJ. PROTAC: an effective targeted protein degradation strategy for cancer therapy. Frontiers in Pharmacology. 2021;12:692574. 

7. Chen L, Wan X, Shan X, Zha W, Fan R. Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy. Mol Diagn Ther. 2022 May;26(3):283–91. 

8. Bashraheel SS, Domling A, Goda SK. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. Biomedicine & Pharmacotherapy. 2020;125:110009. 

9. He S, Gao F, Ma J, Ma H, Dong G, Sheng C. Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer. Angewandte Chemie. 2021 Oct 18;133(43):23487–93. 

10. Burke MR, Smith AR, Zheng G. Overcoming cancer drug resistance utilizing PROTAC technology. Frontiers in Cell and Developmental Biology. 2022;10:872729. 

11. Sun X, Rao Y. PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance. Biochemistry. 2020 Jan 28;59(3):240–9. 12. Yang Y, Gao H, Sun X, Sun Y, Qiu Y, Weng Q, et al. Global PROTAC Toolbox for Degrading BCR–ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567–83.

Share this post